Plate Nº 25 · recorded November 16, 2026

Biology & EvolutionReported finding

3D human muscle model reproduces signs of aging in tissue

Human muscle cells from men aged 17 and 68 formed 3D microtissues that revealed aging-related structural changes, inflammation and significantly weaker contractions in a 2026 study.

By Priya Raman3 min read666 words

In brief

  1. Two male donors, aged 17 and 68, supplied the human muscle cells.
  2. The 3D model used decellularized extracellular matrix and 3D-printed molds to align cells in one direction.
  3. The 68-year-old donor's tissues had thinner fibers, less cell fusion, higher inflammation and significantly weaker contractile force than the 17-year-old donor's tissues.
  4. The paper appeared in Small Science in 2026, with DOI 10.1002/smsc.70386.
  5. FDA Modernization Act 2.0 allows drug approval applications without animal testing.
Team develops 3D biomimetic aging muscle model that can replace animal experiments
Plate Nº 25Team develops 3D biomimetic aging muscle model that can replace animal experiments — IAOM-US / pixabay

By Priya Raman

A 3D human muscle microtissue built from cells donated by a 68-year-old man produced thinner fibers, more inflammation and significantly less contractile force than one built from a 17-year-old man's cells, according to a 2026 study.

The experiment combined human muscle cells from the two male donors with a decellularized extracellular matrix, a scaffold made from the noncellular framework of tissue. Researchers then cultured the mixture in tiny 3D-printed molds until it formed small three-dimensional muscle tissues called microtissues, with cells aligned uniformly in one direction as in actual muscle tissue.

Professor Minseok S. Kim of the Department of New Biology at DGIST led the project with Professor Dong-Woo Cho of the Department of Mechanical Engineering at POSTECH.

What did the aging model reveal?

Professor Kim said: “The significance of this study lies in establishing a foundation for faithfully replicating age-related changes using human-derived cells and evaluating both cellular-level changes and actual muscle contractile function.”

Kim also said: “Given the increasing global interest in human-centered nonclinical testing methods that can replace animal experiments, we aim to refine this model into a valuable research tool for identifying the causes of muscle aging and accurately validating the efficacy of candidate therapeutics.”

Comparative analysis found that age-related changes extended across tissue structure, cell behavior and force production. The older donor's cells produced:

  • Thinner muscle fibers and less cell fusion, meaning fewer muscle cells joined into fibers.
  • Higher inflammation and impaired mitochondrial function, meaning poorer performance of the structures that produce energy.
  • Delayed calcium responses, which trigger muscle contraction, and significantly reduced contractile force, or mechanical pulling strength, after electrical stimulation.

The researchers interpreted the pattern as evidence that the microtissues faithfully reproduced hallmarks of human muscle aging. The model also allowed them to assess morphological changes (changes in structure), molecular changes at the level of gene activity, and contractile function within one platform, rather than observing cell shape or genes alone.

Why did the researchers move beyond flat cell cultures?

Skeletal muscle attaches to bones, enables body movement and is crucial for regulating metabolism, the body's chemical processes. Sarcopenia, the age-related decline in muscle mass and function, reduces mobility and severely undermines quality of life in old age.

Previous research faced substantial biological differences between animal models and humans, while conventional cell cultures on flat, two-dimensional dishes could not fully reproduce the three-dimensional movement and contractile function of actual human muscle. The team designed the 3D microtissue system to address both limits while keeping human cells at the center of the experiment.

Could the model replace animal experiments?

The report says the U.S. Food and Drug Administration (FDA) has recently revised its rules for drug approval under the FDA Modernization Act 2.0 to allow applications without animal testing. The authors expect the artificial muscle model to prove valuable in future work on treatments for sarcopenia.

Their aim is to refine the model into a tool for nonclinical testing, meaning studies conducted outside human trials, rather than to present it now as a finished substitute for animal studies. The experiment used one donor at each age, both men, so it establishes a small proof of concept rather than a population-wide account of muscle aging.

The report does not describe testing a therapy or regulatory acceptance of the microtissue, and Kim said further refinement remains necessary. The two-donor design leaves the findings open to confirmation in larger and more diverse donor samples.

The paper, “A Biomimetic 3D Human Skeletal Muscle Microtissue for Modeling Biological and Functional Hallmarks of Aging,” appeared in Small Science in 2026. The citation names Sohae Yang et al. and gives the DOI as 10.1002/smsc.70386.

The model now gives researchers a single human-cell platform for measuring cellular aging alongside age-related loss of muscle force; replacing animals in drug development remains a goal that requires further refinement and validation.

via phys.org/rss-feed/ (Source)

Filed under

  • muscle-aging
  • 3d-microtissue
  • sarcopenia
  • human-derived-cells
  • contractile-function
Share this article:

More from Priya Raman

Priya Raman

Show full bio

Senior reporter covering people, launches and day-to-day practice in general science news at SciBeat.

425 articles

Nearby plates

« Previous articleNext article »